What is the share price of Supriya Lifescience Ltd (SUPRIYA) today?
The share price of SUPRIYA as on 20th March 2026 is ₹584.20. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Supriya Lifescience Ltd (SUPRIYA) share?
The past returns of Supriya Lifescience Ltd (SUPRIYA) share are- Past 1 week: -1.10%
- Past 1 month: -14.57%
- Past 3 months: -20.82%
- Past 6 months: -21.79%
- Past 1 year: -9.55%
- Past 3 years: 212.41%
- Past 5 years: 49.47%
What are the peers or stocks similar to Supriya Lifescience Ltd (SUPRIYA)?
The peers or stocks similar to Supriya Lifescience Ltd (SUPRIYA) include:What is the dividend yield % of Supriya Lifescience Ltd (SUPRIYA) share?
The current dividend yield of Supriya Lifescience Ltd (SUPRIYA) is 0.17.What is the market cap of Supriya Lifescience Ltd (SUPRIYA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Supriya Lifescience Ltd (SUPRIYA) is ₹4667.20 Cr as of 20th March 2026.What is the 52 week high and low of Supriya Lifescience Ltd (SUPRIYA) share?
The 52-week high of Supriya Lifescience Ltd (SUPRIYA) is ₹842 and the 52-week low is ₹565.What is the PE and PB ratio of Supriya Lifescience Ltd (SUPRIYA) stock?
The P/E (price-to-earnings) ratio of Supriya Lifescience Ltd (SUPRIYA) is 24.83. The P/B (price-to-book) ratio is 4.68.Which sector does Supriya Lifescience Ltd (SUPRIYA) belong to?
Supriya Lifescience Ltd (SUPRIYA) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Supriya Lifescience Ltd (SUPRIYA) shares?
You can directly buy Supriya Lifescience Ltd (SUPRIYA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Supriya Lifescience Ltd
SUPRIYA Share Price
NSE₹584.200.74% (+4.30)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
SUPRIYA Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
SUPRIYA Performance & Key Metrics
SUPRIYA Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 25.19 | 4.68 | 0.17% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 35.10 | 5.54 | 0.61% |
100%
Analysts have suggested that investors can buy this stock
from 2 analysts
Price Upside
Earnings Growth
Rev. Growth
SUPRIYA Company Profile
Supriya Lifescience is a manufacturer of pharmaceutical preparation.
SUNPHARMA
PE Ratio
38.30
38.30
1Y Return
1.53%
1.53%
Buy Reco %
94.12
94.12
TORNTPHARM
PE Ratio
74.57
74.57
1Y Return
32.17%
32.17%
Buy Reco %
81.48
81.48
DRREDDY
PE Ratio
18.76
18.76
1Y Return
9.41%
9.41%
Buy Reco %
51.61
51.61
LUPIN
PE Ratio
31.36
31.36
1Y Return
11.35%
11.35%
Buy Reco %
72.22
72.22
CIPLA
PE Ratio
18.99
18.99
1Y Return
16.91%
16.91%
Buy Reco %
54.84
54.84
SUPRIYA Sentiment Analysis
SUPRIYA Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
SUPRIYA Stock Summary · February 2026
In Q3 FY26, the company achieved an 11% year-on-year revenue growth, driven largely by strong export performance, particularly in the LatAm region, which accounted for 82% of total revenues. Despite a healthy EBITDA margin of 34.9% and a PAT margin of 24.1%, operational challenges, including regulatory delays and inconsistent sales growth, have raised concerns about future capacity and demand. The strategic focus on new product launches, particularly in cardiovascular and ADHD segments, aims to enhance revenue streams, while ongoing investments in facilities like Ambernath are expected to support long-term growth. However, the company must navigate pricing acceptance issues in export markets and regulatory hurdles to fully realize its ambitious revenue targets of INR 1,000 crores by FY27.
SUPRIYA Stock Growth Drivers
SUPRIYA Stock Growth Drivers
7Strong Financial Performance
Supriya Lifescience Limited reported a revenue of INR 206 crores in Q3 FY26, reflecting an
Successful Product Launches
The company successfully launched a key cardiovascular product and introduced an ADHD product, both expected
SUPRIYA Stock Challenges
SUPRIYA Stock Challenges
6Delays in Approvals and Development
The company has experienced significant delays in obtaining environmental clearances for the Isambe site, taking
Inconsistent Sales Growth
The company has reported inconsistent sales growth over the past 12 months, with the latest
SUPRIYA Forecast
SUPRIYA Forecasts
Price
Revenue
Earnings
SUPRIYA Share Price Forecast
SUPRIYA Share Price Forecast
2026
Current
₹584.20
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹584.20
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
SUPRIYA Company Revenue Forecast
SUPRIYA Company Revenue Forecast
2025
Current
₹706.30
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ cr.
2025
Current
₹706.30
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ cr.
SUPRIYA Stock EPS (Earnings Per Share) Forecast
SUPRIYA Stock EPS (Earnings Per Share) Forecast
2025
Current
₹23.35
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹23.35
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
SUPRIYA
SUPRIYA
Income
Balance Sheet
Cash Flow
Quarterly Normal View
SUPRIYA Income Statement
SUPRIYA Income Statement
Quarterly Normal View
| Quarter | sep 2023 | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 142.56 | 143.14 | 160.37 | 162.85 | 168.62 | 187.75 | 187.08 | 147.75 | 202.56 | 209.05 | ||||||||||
Operating & Other expenses | 108.34 | 98.59 | 102.68 | 98.09 | 101.39 | 119.70 | 116.53 | 93.37 | 127.19 | 134.82 | ||||||||||
EBITDA | 34.22 | 44.55 | 57.69 | 64.76 | 67.23 | 68.05 | 70.55 | 54.38 | 75.37 | 74.23 | ||||||||||
| Depreciation/Amortization | 3.98 | 3.96 | 3.91 | 4.66 | 4.74 | 4.96 | 6.08 | 6.45 | 6.64 | 6.82 | ||||||||||
| PBIT | 30.24 | 40.59 | 53.78 | 60.10 | 62.49 | 63.09 | 64.47 | 47.93 | 68.73 | 67.41 | ||||||||||
| Interest & Other Items | 0.46 | 0.49 | 0.60 | 0.34 | 0.43 | 0.51 | 0.42 | 0.51 | 0.42 | 0.49 | ||||||||||
| PBT | 29.78 | 40.10 | 53.18 | 59.76 | 62.06 | 62.58 | 64.05 | 47.42 | 68.31 | 66.92 | ||||||||||
| Taxes & Other Items | 5.90 | 10.32 | 16.24 | 15.13 | 15.92 | 15.80 | 13.68 | 12.63 | 17.89 | 17.24 | ||||||||||
| Net Income | 23.88 | 29.78 | 36.94 | 44.63 | 46.14 | 46.78 | 50.37 | 34.79 | 50.42 | 49.68 | ||||||||||
| EPS | 2.97 | 3.70 | 4.59 | 5.54 | 5.71 | 5.82 | 6.29 | 4.32 | 6.27 | 6.17 |
SUPRIYA Company Updates
FY 2026FY 2026
Investor Presentation
Feb 9PDF
Nov 12PDF
Aug 13PDF
SUPRIYA Stock Peers
SUPRIYA Past Performance & Peer Comparison
SUPRIYA Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Supriya Lifescience Ltd | 24.83 | 4.68 | 0.17% |
| Sun Pharmaceutical Industries Ltd | 38.30 | 5.77 | 0.92% |
| Torrent Pharmaceuticals Ltd | 74.57 | 18.77 | 0.76% |
| Dr Reddy's Laboratories Ltd | 18.76 | 3.13 | 0.63% |
SUPRIYA Stock Price Comparison
Compare SUPRIYA with any stock or ETFCompare SUPRIYA with any stock or ETF
SUPRIYA
SUPRIYA Holdings
SUPRIYA Shareholdings
SUPRIYA Promoter Holdings Trend
SUPRIYA Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
SUPRIYA Institutional Holdings Trend
SUPRIYA Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
SUPRIYA Shareholding Pattern
SUPRIYA Shareholding Pattern
SUPRIYA Shareholding History
SUPRIYA Shareholding History
Foreign Institutions
Mutual Funds Invested in SUPRIYA
Mutual Funds Invested in SUPRIYA
No mutual funds holding trends are available
Top 5 Mutual Funds holding Supriya Lifescience Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.7361% | Percentage of the fund’s portfolio invested in the stock 1.12% | Change in the portfolio weight of the stock over the last 3 months 1.12% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 42/47 (-25) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.2567% | Percentage of the fund’s portfolio invested in the stock 1.61% | Change in the portfolio weight of the stock over the last 3 months 0.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 11/113 (+8) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.1452% | Percentage of the fund’s portfolio invested in the stock 3.57% | Change in the portfolio weight of the stock over the last 3 months 0.42% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 3/57 (+1) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing SUPRIYA stock
smallcases containing SUPRIYA stock
Looks like this stock is not in any smallcase yet.
SUPRIYA Events
SUPRIYA Events
SUPRIYA Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
SUPRIYA has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.17%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.72 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
SUPRIYA Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
SUPRIYA has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.17%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.72 every year
SUPRIYA Upcoming Dividends
SUPRIYA Upcoming Dividends
No upcoming dividends are available
SUPRIYA Past Dividends
SUPRIYA Past Dividends
Cash Dividend
Ex DateEx DateSep 4, 2025
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Sep 4, 2025
Cash Dividend
Ex DateEx DateSep 20, 2024
Final
Final | Div/Share: ₹0.80
Dividend/Share
₹0.80
Ex DateEx Date
Sep 20, 2024
Cash Dividend
Ex DateEx DateSep 15, 2023
Final
Final | Div/Share: ₹0.60
Dividend/Share
₹0.60
Ex DateEx Date
Sep 15, 2023
Cash Dividend
Ex DateEx DateSep 1, 2022
Final
Final | Div/Share: ₹0.60
Dividend/Share
₹0.60
Ex DateEx Date
Sep 1, 2022
SUPRIYA Stock News & Opinions
SUPRIYA Stock News & Opinions
Articles & Videos
Earnings
Supriya Lifescience standalone net profit rises 6.20% in the December 2025 quarter
Net profit of Supriya Lifescience rose 6.20% to Rs 49.68 crore in the quarter ended December 2025 as against Rs 46.78 crore during the previous quarter ended December 2024. Sales rose 11.20% to Rs 206.44 crore in the quarter ended December 2025 as against Rs 185.65 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales206.44185.65 11 OPM %34.9235.52 - PBDT74.2067.54 10 PBT67.3862.58 8 NP49.6846.78 6 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Supriya Lifesciences to discuss results
Supriya Lifesciences will hold a meeting of the Board of Directors of the Company on 9 February 2026.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Supriya Lifescience standalone net profit rises 9.27% in the September 2025 quarter
Net profit of Supriya Lifescience rose 9.27% to Rs 50.43 crore in the quarter ended September 2025 as against Rs 46.15 crore during the previous quarter ended September 2024. Sales rose 20.31% to Rs 199.83 crore in the quarter ended September 2025 as against Rs 166.10 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales199.83166.10 20 OPM %36.3638.96 - PBDT74.9666.81 12 PBT68.3262.07 10 NP50.4346.15 9 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Supriya Lifesciences to hold board meeting
Supriya Lifesciences will hold a meeting of the Board of Directors of the Company on 12 November 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Supriya Lifesciences to hold AGM
Supriya Lifesciences announced that the Annual General Meeting(AGM) of the company will be held on 24 September 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Supriya Lifescience standalone net profit declines 22.07% in the June 2025 quarter
Net profit of Supriya Lifescience declined 22.07% to Rs 34.79 crore in the quarter ended June 2025 as against Rs 44.64 crore during the previous quarter ended June 2024. Sales declined 9.69% to Rs 145.07 crore in the quarter ended June 2025 as against Rs 160.63 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales145.07160.63 -10 OPM %35.6438.94 - PBDT53.8764.43 -16 PBT47.4259.77 -21 NP34.7944.64 -22 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Supriya Lifesciences to table results
Supriya Lifesciences will hold a meeting of the Board of Directors of the Company on 13 August 2025.Powered by Capital Market - Live
7 months agoCapital Market - Live
Earnings
Supriya Lifescience standalone net profit rises 36.42% in the March 2025 quarter
Net profit of Supriya Lifescience rose 36.42% to Rs 50.38 crore in the quarter ended March 2025 as against Rs 36.93 crore during the previous quarter ended March 2024. Sales rose 16.39% to Rs 184.11 crore in the quarter ended March 2025 as against Rs 158.18 crore during the previous quarter ended March 2024. For the full year,net profit rose 57.80% to Rs 187.96 crore in the year ended March 2025 as against Rs 119.11 crore during the previous year ended March 2024. Sales rose 22.11% to Rs 696.49 crore in the year ended March 2025 as against Rs 570.37 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales184.11158.18 16 696.49570.37 22 OPM %36.7135.08 -37.4430.33 - PBDT70.1457.08 23 268.93181.50 48 PBT64.0653.17 20 248.49165.69 50 NP50.3836.93 36 187.96119.11 58 Powered by Capital Market - Live
9 months agoCapital Market - Live
Corporate
Board of Supriya Lifesciences recommends final dividend
Supriya Lifesciences announced that the Board of Directors of the Company at its meeting held on 27 May 2025, inter alia, have recommended the final dividend of Rs 1 per equity Share (i.e. 50%) , subject to the approval of the shareholders.Powered by Capital Market - Live
9 months agoCapital Market - Live
Corporate
Supriya Lifesciences to announce Quarterly Result
Supriya Lifesciences will hold a meeting of the Board of Directors of the Company on 27 May 2025.Powered by Capital Market - Live
10 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 16.96%, vs industry avg of 9.88%
Over the last 5 years, market share increased from 0.13% to 0.17%
Over the last 5 years, net income has grown at a yearly rate of 20.7%, vs industry avg of 19.69%